Day One Biopharmaceuticals

54 articles about Day One Biopharmaceuticals

• Day One Receives FDA Rare Pediatric Disease Designation for DAY101 for the Treatment of Pediatric Low-Grade Glioma

  7/27/2021

  Day One Biopharmaceuticals announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead product candidate, DAY101, for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children.

• Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

  6/21/2021

  Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, announced that the European Commission has granted orphan designation for the Company’s lead product candidate, DAY101, for the treatment of glioma.

• 

  May Was a Busy Month with Seven Biotech IPOs

  6/1/2021

  There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.

• Day One Announces Pricing of Upsized Initial Public Offering

  5/26/2021

  Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share

• 

  Money on the Move: May 5 - 11

  5/12/2021

  Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.  

• Day One Announces First Patient Dosed in FIREFLY-1 Pivotal Phase 2 Clinical Trial of DAY101 in Pediatric Progressive Low-Grade Glioma

  5/11/2021

  FIREFLY-1 is designed to support regulatory registration of DAY101 in pediatric low-grade glioma (pLGG), which is the most common form of childhood brain cancer and has no approved therapies DAY101 is an oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor with demonstrated evidence of anti-tumor activity in pLGG

• 

  IPO and SPAC Boom Continues as More Life Sciences Companies Announce Terms

  5/7/2021

  With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.  

• Day One Appoints Saira Ramasastry to Board of Directors

  4/12/2021

  Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the appointment of Ms. Saira Ramasastry to the Company’s board of directors.

• Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize MEK Inhibitor Pimasertib

  2/23/2021

  Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B Day One plans to evaluate the combination of pimasertib and DAY101, the Company’s clinical-stage pan-RAF kinase inhibitor, in patients ≥12 years of age with advanced solid tumors

• Day One Appoints Charles N. York II as Chief Operating and Financial Officer and Expands Board of Directors with the Addition of Natalie Holles

  2/17/2021

  Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced the appointment of Charles N. York II as chief operating and financial officer and the addition of Natalie Holles to the Company’s board of directors.

• Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

  2/10/2021

  Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors

• Day One Announces Preliminary Phase 1 Results for DAY101 in Pediatric Low-Grade Glioma, Receipt of Breakthrough Therapy Designation (BTD) and New Phase 2 Study

  11/19/2020

  Day One Biopharmaceuticals, a company driven to develop promising new oncology therapies for both children and adults living with cancer, announced interim results from PNOC014, an ongoing Phase 1 investigator-sponsored study conducted by Dana-Farber and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) of DAY101 in children with radiographically recurrent/progressive low-grade gliomas and other MAP kinase pathway activated tumors.

• Day One Announces Expansion of Executive Leadership Team and Board of Directors, including Jeremy Bender, Lisa Bowers, and John Josey

  9/23/2020

  Day One announces today the expansion of its executive team and Board of Directors.

• Day One Biopharmaceuticals shares plans to rapidly develop new cancer treatments for people of all ages and announces $60M Series A funding and lead clinical-stage program acquired through Takeda

  5/21/2020

  Day One Biopharmaceuticals, LLC. Using new insights from the biology of pediatric cancer, Day One Biopharmaceuticals develops promising new oncology therapies that change outcomes for people of all ages. Today, Day One unveils its team, $60M Series A financing, and announces its first promising clinical-stage oncology treatment, which Day One acquired through Takeda Pharmaceutical Company Limited.